Imiquimod 5%: A Successful Treatment for Pseudolymphoma
نویسندگان
چکیده
منابع مشابه
Successful Treatment of Earlobe Keloids with Imiquimod after Shave Excision
There are various methods to treat keloid. However, the recurrence of keloidal lesions seems important in this regard. Herein, we report a case of successful treatment of earlobe keloids with imiquimod after shave excision.
متن کاملSuccessful treatment of vulvar intraepithelial neoplasia with topical imiquimod 5% cream in a lung transplanted patient.
Sir, Imiquimod, an immune response modi® er, has been successful in the treatment of external genital and perianal warts caused by low-risk HPV, usually types 6 or 11 (1). The drug’s antiviral and antitumour properties are thought to be due to its induction of cytokines, which stimulate a T-helper 1 or cell-mediated immune response. Recently, it has been shown that imiquimod may potentially be ...
متن کاملTreatment of infantile hemangioma with topical imiquimod 5% cream
Background: Infantile hemangioma is a congenital vascularmalformation. Although almost all cases are self-limiting, treatmentis sometimes necessary. According to previous studies, topicalimiquimod induces resolution of lesions with an acceptable safetyprofile. The aim of the present study was to evaluate the effect ofthis topical treatment on Iranian infantile hemangioma patients.Method: Patien...
متن کاملSuccessful treatment of anal and perianal condyloma acuminata with imiquimod.
Condyloma acuminata are genital or perianal warts caused mainly by human papillomavirus (HPV) types 6 and 11. In HIV-positive patients and in men who have sex with men (MSM), the prevalence of anal HPV infection is particularly high (45-95%) (1). Current therapies for condylorna acuminata include surgical excision and ablation by cryotherapy, electrocautery, or lasers. Imiquimod, a topical immu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Acta Dermato Venereologica
سال: 2014
ISSN: 0001-5555
DOI: 10.2340/00015555-1730